42 assets in Renal Carcinoma

Therapeutic assets addressing Renal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Renal Carcinoma	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	BBB (72)
Cabozantinib Renal Carcinoma	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	BB (70)
Ipilimumab Renal Carcinoma	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	BB (69)
Pembrolizumab Renal Carcinoma	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	BB (69)
Axitinib Renal Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (60)
Epinephrine Renal Carcinoma	Wake Forest University Health Sciences	P3	B (60)
Ketorolac Renal Carcinoma	Wake Forest University Health Sciences	P3	B (60)
Lenvatinib Renal Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (60)
Marcaine Renal Carcinoma	Wake Forest University Health Sciences	P3	B (60)
Ropivacaine Renal Carcinoma	Wake Forest University Health Sciences	P3	B (60)
Clonidine Renal Carcinoma	Wake Forest University Health Sciences	P3	B (59)
Binimetinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Capivasertib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Casdatifan Renal Carcinoma	Dana-Farber Cancer Institute	P2	CCC (53)
Crizotinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dasatinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Defactinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fexagratinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Renal Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Osimertinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pertuzumab Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Relatlimab Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Sapanisertib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trametinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Urea Renal Carcinoma	Zhen Wang, MD	P2	CCC (53)
Vismodegib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Zimberelimab Renal Carcinoma	Dana-Farber Cancer Institute	P2	CCC (53)
Adavosertib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Pyruvate Renal Carcinoma	Zhen Wang, MD	P2	CCC (51)
Taselisib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Copanlisib Renal Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
Entinostat Renal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
Cytokine Induced Memory-Like Natural Killer Cells Renal Carcinoma	Dana-Farber Cancer Institute	Early P1	C (39)